Online Inquiry

Please note that we are not a pharmacy or clinic, so we are unable to see patients and do not offer diagnostic and treatment services for individuals.


Recurrent Respiratory Papillomatosis (RRP)

Recurrent respiratory papillomatosis (RRP) is a rare and challenging benign airway tumor that is caused by HPV infection. This unique condition is characterized by wart-like growths in the airways, which can lead to voice impairment and airway obstruction. In the field of RRP disease research, our company possesses extensive experience and expertise, which can offer valuable support to further your investigations into this rare disease.

Introduction to RRP

Recurrent respiratory papillomatosis (RRP) is a rare disease, and the incidence rate slightly varies between children and adults, with approximately 4.3 cases per 100,000 children and 1.8 cases per 100,000 adults. Chronic viral disease is characterized by the growth of benign tumors (papillomas) in the respiratory tract, primarily the larynx and vocal cords. Individuals with RRP may experience symptoms such as hoarseness, chronic cough, difficulty breathing, stridor, and recurrent respiratory infections.

The signaling pathway of RRP induced by HPV 6/11.Fig.1 Outline of HPV type 6 and 11 infection pathways. (Ouda, A. M., et al., 2021)

Pathogenesis of RRP

Pathogenesis of RRP involves initial infection, latency, and reactivation of the virus. RRP is caused by the HPV virus entering the body through mucosal surfaces, such as the respiratory tract, and infects the cells, causing them to multiply rapidly and form papillomas. The papillomas can grow and spread, leading to airway obstruction and voice changes. In severe cases, the tumors can extend into the lower respiratory tract and lungs, further exacerbating the condition.

Therapeutics of RRP

Small Molecule Drugs Therapy

Small molecule drugs, such as antiviral drugs (cidofovir and interferon) have demonstrated efficacy in therapeutic. Additionally, EGFR inhibitors (gefitinib), immunomodulatory drugs (alpha-interferon), and COX-2 inhibitors (celecoxib) have shown promise in suppressing papilloma growth.

Monoclonal Antibodies Therapy

Monoclonal antibody therapy has emerged as a promising approach for managing papilloma. VEGF pathway inhibitors (bevacizumab and avastin) and anti-PD-L1 monoclonal antibodies (avelumab) have shown the potential to reduce the size of RRP and improve therapeutic outcomes.

Vaccines Therapy

Vaccines play a crucial role in preventing and managing papilloma. HPV vaccines, such as Gardasil-9 and Cervarix, have been developed to induce humoral immune responses to prevent latent HPV infection, thereby reducing the severity of the disease and minimizing the risk of recurrence.

Our Services

Our company specializes in rare disease research and possesses a wealth of expertise in the field of RRP. We can provide animal models and therapeutic platforms, enabling researchers to delve into the intricacies of the disease's pathogenesis and explore novel therapeutic avenues.

Platforms of RRP Therapy Development

Animal Models of RRP

In the realm of RRP, animal models have emerged as indispensable tools for unraveling the complexities of this disease. Our company can provide virus-induced and genetically engineered animal models to support your research in this field and promote the development of novel therapeutic strategies.

Virus-induced Models
Employing intranasal or laryngeal inoculation techniques can induce the development of respiratory papillomatosis in animals. This model offers researchers a unique opportunity to study the dynamic virus-host interaction.
Optional Models
  • CRPV model
  • COPV model
Genetically Engineered Models
Genetically engineered models have also proven instrumental in RRP research. Manipulating the mouse genome to express viral oncoproteins, can lead to the development of epithelial hyperplasia and malignancy.
Optional Models
  • E6/E7 transgenic model
Xenograft Models
In this model, human papillomatous tissues are transplanted into animals with low immune function, which can then be used for researching different therapeutic interventions.
Optional Models
  • CAM RRP xenograft model
  • NOD-scid-IL2Rgammanull (NSG) xenograft model
  • NOD/SCID xenograft model
Optional Species Mice, Rats, Rabbit, Non-Human Primates, Others

Our company offers a range of services tailored to support your research in RRP endeavors, which can support your pharmacokinetics analysis and drug safety evaluation. If you are interested in our services, please feel free to contact us for more details and quotation information of related services.


  • Ouda, Amr Mohamed et al. "HPV and Recurrent Respiratory Papillomatosis: A Brief Review." Life (Basel, Switzerland) 11.11 (2021): 1279.
  • Benedict, Jacob J, and Craig S Derkay. "Recurrent respiratory papillomatosis: A 2020 perspective." Laryngoscope investigative otolaryngology 6.2 (2021): 340-345.

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.

Related Services

Copyright © Protheragen. All rights reserves.